At A Glance
1
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.
2
No significant events in the past 90 days.
—
Market Cap
—
Revenue
—
Net Income
Employees6
Fundamentals
How The Business Makes Money
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Industry Medical - Diagnostics & Research
Activity
What Changed Recently
No significant events in the past 90 days.
Analyst View
Company Profile
CIKUNKNOWN_EPGNF
ISINDE000A37FT41
Phone49 30 243 450
AddressGeneststrasse 5, Heidelberg, 10829, DE
SEC EDGAR